| Bivalirudin: in patients with ST-segment elevation myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 20426499 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bivalirudin is a synthetic 20 amino acid polypeptide that directly inhibits both fibrin-bound and soluble thrombin. In the randomized, open-label, multicentre HORIZONS-AMI trial in patients with ST-segment elevation myocardial infarction (STEMI) who were undergoing primary percutaneous coronary intervention (PCI), compared with unfractionated heparin (UFH) plus a glycoprotein (GP) IIb/IIIa inhibitor, bivalirudin was associated with a significantly lower 30-day rate of net adverse clinical events that was largely due to the significantly lower 30-day rate of non-coronary-artery bypass grafting major bleeding. There was no significant between-group difference in the 30-day rate of major adverse cardiovascular events. These 30-day clinical outcomes were maintained at the 1- and 2-year follow-up. Bivalirudin, compared with UFH plus a GP IIb/IIIa inhibitor, was associated with lower short- (30-day) and long- (1- and 2-year) term overall and cardiac mortality rates. Although there was an increased risk of acute stent thrombosis within 24 hours in recipients of bivalirudin compared with UFH plus a GP IIb/IIIa inhibitor, there was no significant between-group difference between 24 hours and 30 days, <or=30 days, <or=1 year or <or=2 years. |
| | |
Authors:
|
Monique P Curran |
Related Documents
:
|
16401379 - Appropriate invasive and conservative treatment approaches for patients with st-elevati... 9597519 - Rationale and clinical evidence for the use of gp iib/iiia inhibitors in acute coronary... 12008169 - Optimal strategy for administering enoxaparin to patients undergoing coronary angiograp... 8641009 - Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-... 17161049 - Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk pat... 7982419 - Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfar... 2787529 - Surgery of ventricular tachycardia and ventricular fibrillation in patients with corona... 15728039 - Sevoflurane but not propofol preserves myocardial function during minimally invasive di... 21406439 - Right ventricular mechanical dispersion is related to malignant arrhythmias: a study of... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drugs Volume: 70 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-04-29 Completed Date: 2010-07-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 909-18 Citation Subset: IM |
Affiliation:
|
Adis, Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Coagulation
/
drug effects Clinical Trials as Topic Electrocardiography Hirudins / adverse effects, pharmacokinetics, pharmacology Humans Myocardial Infarction / blood, diagnosis, drug therapy*, metabolism Peptide Fragments / adverse effects, pharmacokinetics, pharmacology, therapeutic use* Recombinant Proteins / adverse effects, pharmacokinetics, pharmacology, therapeutic use Thrombin / antagonists & inhibitors* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hirudins; 0/Peptide Fragments; 0/Recombinant Proteins; 128270-60-0/bivalirudin; EC 3.4.21.5/Thrombin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Antiplatelet drugs - do we need new options?: with a reappraisal of direct thromboxane inhibitors.
Next Document: Methylnaltrexone.